ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026
Consolidated revenue of €1.9 million as of the end of June 2026
Cash balance of €26.9 million as of June 30, 2026 prior to receiving Research Tax Credits and grants under the France 2030 plan
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, today provides an update on its activity and cash position as of June 30, 2026.
